Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sputnik V

- PMLiVE

Annual COVID-19 jabs likely, says Pfizer head

Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

- PMLiVE

Booster plans expanded to combat Omicron

As booster jab campaigns against COVID-19 are expanded in many countries, data from Israel backs up the benefits of being boosted

- PMLiVE

US regulators set to approve oral antiviral against COVID-19

The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next

- PMLiVE

COVID-19 vaccines against Omicron may be fast-tracked

Regulators including the Food and Drug Administration (FDA) may treat Omicron-specific mRNA vaccines like seasonal flu vaccines, speeding up approval

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

New COVID variant causing concern

An ‘unusual constellation of mutations’ in a new variant of the virus that causes COVID-19 has scientists worried that it could impact the efficacy of vaccines

- PMLiVE

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy

- PMLiVE

US FDA expands COVID-19 booster jabs to all adults

All Americans 18 and over are now eligible to receive a booster shot of either the Pfizer/BioNTech or Moderna COVID-19 vaccines

- PMLiVE

US government to pay $5.3bn for Pfizer‘s Paxlovid

If approved by the FDA, the US government will purchase 10 million courses of Pfizer’s anti-COVID protease inhibitor antiviral therapy, Paxlovid, this year and into 2022

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

- PMLiVE

UK expands COVID-19 vaccine plans as winter approaches

The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds

- PMLiVE

US President Biden nominates Robert Califf as FDA commissioner

Biden said Califf has both the experience and expertise to lead the FDA “during a critical time in our nation’s fight” against the coronavirus pandemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links